Pathstone Holdings LLC Buys 632 Shares of Balchem Co. (NASDAQ:BCPC)

Pathstone Holdings LLC lifted its holdings in shares of Balchem Co. (NASDAQ:BCPC) by 6.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,361 shares of the basic materials company’s stock after purchasing an additional 632 shares during the quarter. Pathstone Holdings LLC’s holdings in Balchem were worth $1,824,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in shares of Balchem during the third quarter worth about $35,000. GAMMA Investing LLC raised its position in shares of Balchem by 73.4% during the third quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company’s stock worth $148,000 after purchasing an additional 356 shares during the period. Blue Trust Inc. raised its position in Balchem by 642.5% in the 3rd quarter. Blue Trust Inc. now owns 839 shares of the basic materials company’s stock valued at $148,000 after buying an additional 726 shares during the last quarter. TD Asset Management Inc acquired a new stake in Balchem in the 2nd quarter valued at approximately $200,000. Finally, Heritage Family Offices LLP acquired a new stake in Balchem in the 2nd quarter valued at approximately $206,000. Institutional investors and hedge funds own 87.91% of the company’s stock.

Balchem Stock Down 1.4 %

Shares of Balchem stock opened at $179.69 on Thursday. The business’s 50 day simple moving average is $174.23 and its 200 day simple moving average is $167.08. Balchem Co. has a 52-week low of $120.87 and a 52-week high of $186.03. The firm has a market cap of $5.84 billion, a PE ratio of 49.01, a P/E/G ratio of 5.46 and a beta of 0.65. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.90 and a current ratio of 2.98.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BCPC. StockNews.com raised Balchem from a “hold” rating to a “buy” rating in a research report on Monday, October 28th. HC Wainwright lifted their target price on Balchem from $185.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, November 4th.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.